Quick Answer
Tarsus Pharmaceuticals, Inc. reported Net Income Loss of -$66.42 million for the year ending 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +42.5% in Net Income Loss from 2024 to 2025.
- This data is from Tarsus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$1.75 million | Q2 2019: -$831.0 thousand | Q3 2019: -$681.0 thousand | Q1 2020: -$1.96 million | Q2 2020: -$3.25 million | Q3 2020: -$10.14 million | Q1 2021: $10.38 million | Q2 2021: $6.35 million | Q3 2021: -$15.70 million | Q1 2022: -$20.24 million | Q2 2022: -$5.74 million | Q3 2022: -$22.51 million | Q1 2023: -$23.42 million | Q2 2023: -$31.42 million | Q3 2023: -$39.15 million | Q1 2024: -$35.73 million | Q2 2024: -$33.29 million | Q3 2024: -$23.42 million | Q1 2025: -$25.12 million | Q2 2025: -$20.34 million | Q3 2025: -$12.59 million.
- Over the full 8 years of available data (2018 to 2025), Tarsus Pharmaceuticals, Inc.'s Net Income Loss has declined by 4,935.5%.
- Historical annual values: Fiscal year 2025: -$66.42 million | Fiscal year 2024: -$115.55 million | Fiscal year 2023: -$135.89 million | Fiscal year 2022: -$62.09 million | Fiscal year 2021: -$13.83 million | Fiscal year 2020: -$26.81 million | Fiscal year 2019: -$4.67 million | Fiscal year 2018: -$1.32 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: